Search results for: Real World Evidence (RWE)
Filter search results
How Important are the Differences Between the EQ-5D-5L and EQ-5D-3L Value Sets?
24 March 2017
…which has been used for two decades, e.g. in evidence submitted to NICE (Dolan, 1997); – a ‘crosswalk’ value set (van Hout et al., 2012), which maps patients’ EQ-5D-5L data…
Shalu Jain
29 June 2023
…inform evidence-based decision making. She uses a diverse range of methodologies for evidence synthesis to inform policymaking and practices. She works in an area-agnostic manner, utilizing data to solve complex…
A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
19 May 2023
…poor incentives for high-value diagnostic innovation, low willingness to pay for AMR diagnostics from local budget holders, and low evidence of value at the point of adoption A novel payment…
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…Hampson, G., Towse, A., Pearson, S., Dreitlein, W., Henshall, C. (2017). Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. Nov 16. DOI…
Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind?
4 April 2018
…Mott considers whether quantitative patient preference data has a role to play in health technology assessment (HTA) decision making. Evidence on patient preferences can be incorporated into HTA processes either…
Valuing Health at the End of Life: A Review of Stated Preference Studies in the Social Sciences Literature
9 April 2018
…the review to capture studies published until October 2017. The evidence is mixed overall, with eight studies that report evidence consistent with a premium for end of life treatments…
The Impact of New Medicines in the NHS: 70 Years of Innovation
14 August 2018
…of the most important medicines to have been brought to market, and from a review of the literature and evidence base we attempt to quantify the benefits of these key…
OHE Response to Public Consultation on NICE Principles
7 February 2019
…service users, carers and the wider public are involved in defining the scope of NICE products and are invited to submit evidence for its advisory committees to consider. This seems…
Unlocking the Value of Combination Therapies
9 July 2024
…of evidence and the ability to generate relevant evidence. The discussion between manufacturers and payers could also be supplemented by the shares generated using the IV and MR approaches. This…